Horizon Therapeutics
HZNP
$0.04 (0.03%)
1D
1W
3M
1Y
5Y
ALL
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • about 5 months ago • HZNP
5 Biotech Acquisition Targets To Accumulate In 2024Seeking Alpha • about 7 months ago • HZNP
Amgen: Horizon's Pipeline May Be Too ExpensiveReuters • about 7 months ago • HZNP
Amgen completes $27.8 bln Horizon dealZacks Investment Research • about 8 months ago • HZNP
Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?MarketBeat • about 8 months ago • HZNP
3 Growth Stocks to Buy in SeptemberCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.